Inhibrx EBITDA
¿Qué es el EBITDA de Inhibrx?
El EBITDA de Inhibrx, Inc. es -$111.79
¿Cuál es la definición de EBITDA?
El EBITDA es la ganancia de una compañía antes de intereses, impuestos, depreciación y amortización y es una medida contable calculada usando las ganancias netas de la compañía, antes de que se resten los gastos de interés, los impuestos, la depreciación y la amortización, como un proxy de la rentabilidad operativa actual de la compañía.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA de compañías en Sector Health Care en NASDAQ en comparadas con Inhibrx
¿Qué hace Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Empresas con ebitda similar a Inhibrx
- Geron tiene EBITDA de -$113.06
- Pliant Therapeutics tiene EBITDA de -$112.61
- Avalara Inc tiene EBITDA de -$112.60
- Christine International tiene EBITDA de -¥112.46
- Albireo Pharma Inc tiene EBITDA de -$112.20
- Kadmon tiene EBITDA de -$112.01
- Inhibrx tiene EBITDA de -$111.79
- Apollo Future Mobility tiene EBITDA de -HKD$111.73
- Ballard Power Systems tiene EBITDA de -$111.66
- Housing Development and Infrastructure tiene EBITDA de -₨111.53
- ALX Oncology tiene EBITDA de -$111.40
- Provention Bio tiene EBITDA de -$111.35
- Litian Pictures tiene EBITDA de -¥110.92